Internal Reference Number: FOI_7625
Date Request Received: 18/12/2023 00:00:00
Date Request Replied To: 27/12/2023 00:00:00
This response was sent via: By Email
Request Summary: Request on Nivolumab
Request Category: Companies
| Question Number 1: . In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma? 鈥� Ipilimumab (monotherapy) 鈥� Nivolumab (monotherapy) 鈥� Nivolumab AND Ipilimumab (combination) 鈥� Pembrolizumab 鈥� Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) 鈥� Other active systemic anti-cancer therapy *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. | |
| Answer To Question 1: 0 - we do not treat melanoma with SACt at this Trust. | |
| Question Number 2: In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal cell carcinoma? 鈥� Nivolumab (monotherapy) 鈥� Nivolumab + Ipilimumab 鈥� Nivolumab + Cabozantinib 鈥� Avelumab + Axitinib *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. | |
| Answer To Question 2: 0 - we do not treat renal cell carcinoma with SACt at this Trust. | |
| Question Number 3: In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer: 鈥� Nivolumab monotherapy or in combination with Ipilimumab 鈥� Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 鈥� Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. | |
| Answer To Question 3: 鈥� Nivolumab monotherapy or in combination with Ipilimumab - 0 鈥� Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 0 鈥� Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of 看片软件 Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
